Moderna’s Covid-19 vaccine sales forecast slashed amidst strong competition
Pharmaceutical Technology
JANUARY 25, 2023
It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.
Let's personalize your content